General MedicationsORALStandard
VOYDEYA
DANICOPAN
Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary
Approval overview VOYDEYA is listed in Drugs@FDA under application 218037 (NDA).
Review priority: N/A Marketing status: Prescription Active ingredient DANICOPAN Form and strength TABLET;ORAL - 50MG Sponsor ALEXION PHARMS INC Submission history Latest submission status date: 2025-06-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview VOYDEYA is listed in Drugs@FDA under application 218037 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient DANICOPAN Form and strength TABLET;ORAL - 50MG Sponsor ALEXION PHARMS INC Submission history Latest submission status date: 2025-06-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.